Xiaorui Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaorui Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Tao Sun
Breast Internal Medicine Ward 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China
2 shared publications - Deqian Xie
Department of Urology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China
1 shared publication - Dequan Liu
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China
1 shared publication - Guangzhen Wu
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
1 shared publication Guilian Liang
Department of Oncology Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute Shenyang China
1 shared publicationLiping Xiao
Department of Oncology Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute Shenyang China
1 shared publication
Latest Publications
- 7 September 2026
- Published by Wiley in Medicinal Research Reviews
N‐Myristoylation: A Central Hub Integrating Tumor Signaling, Metabolism, and Immunity for Precision Therapy
Lipid modifications are critical for membrane anchoring and signal transduction. N‐myristoylation, catalyzed by NMT1/2, irreversibly attaches myristic acid to N‐terminal glycine residues, enabling stable membrane localization and crosstalk with other post‐translational modifications. This review traces NMT research from structural characterization to substrate profiling, highlighting the ordered double‐substitution catalytic mechanism and variations in substrate recognition. While prior reviews have covered NMT biochemistry and innate immunity, we emphasize underappreciated roles of N‐myristoylation in metabolic vulnerability, immune evasion, and acquired resistance to targeted therapies and immunotherapies. We discuss how exogenous myristic acid from dietary sources fuels oncogenic signaling, and how N‐myristoylation regulates key signaling pathways (PI3K/AKT, MAPK, ferroptosis) and targets (Src, AMPK, EZH2) to drive immunosuppressive and pro‐tumor phenotypes. Antitumor potential of NMT inhibitors (e.g., B‐13, Zelenirstat) and allosteric ABL1 inhibitors (asciminib) is evaluated. Recent methodological advances (including metabolic labeling, click chemistry, spatial proteomics, and computational simulations) are reviewed. However, translational challenges such as biomarker absence, blood–brain barrier limitations, and functional redundancy remain. Addressing these will require combination therapies tailored to specific mutational, metabolic, and immune profiles. In summary, N‐myristoylation integrates signaling, metabolism, and immunity, offering a rationale for future precision oncology.
- 7 September 2026
- Published by Wiley in Medicinal Research Reviews
N‐Myristoylation: A Central Hub Integrating Tumor Signaling, Metabolism, and Immunity for Precision Therapy
Lipid modifications are critical for membrane anchoring and signal transduction. N‐myristoylation, catalyzed by NMT1/2, irreversibly attaches myristic acid to N‐terminal glycine residues, enabling stable membrane localization and crosstalk with other post‐translational modifications. This review traces NMT research from structural characterization to substrate profiling, highlighting the ordered double‐substitution catalytic mechanism and variations in substrate recognition. While prior reviews have covered NMT biochemistry and innate immunity, we emphasize underappreciated roles of N‐myristoylation in metabolic vulnerability, immune evasion, and acquired resistance to targeted therapies and immunotherapies. We discuss how exogenous myristic acid from dietary sources fuels oncogenic signaling, and how N‐myristoylation regulates key signaling pathways (PI3K/AKT, MAPK, ferroptosis) and targets (Src, AMPK, EZH2) to drive immunosuppressive and pro‐tumor phenotypes. Antitumor potential of NMT inhibitors (e.g., B‐13, Zelenirstat) and allosteric ABL1 inhibitors (asciminib) is evaluated. Recent methodological advances (including metabolic labeling, click chemistry, spatial proteomics, and computational simulations) are reviewed. However, translational challenges such as biomarker absence, blood–brain barrier limitations, and functional redundancy remain. Addressing these will require combination therapies tailored to specific mutational, metabolic, and immune profiles. In summary, N‐myristoylation integrates signaling, metabolism, and immunity, offering a rationale for future precision oncology.
Role of BARX1 in Development and Disease
Homeobox genes encode diverse proteins, including proteins with highly conserved DNA‐binding domains, and are essential for organismal growth, cell differentiation, organ development, and diverse physiological processes associated with diseases. BARX1 encodes a transcription factor containing the BarH1‐like homeodomain. This gene plays a significant role in the development of various tissues and is closely associated with the pathogenesis and progression of numerous diseases. In this review, we provide a comprehensive overview of the functional networks and mechanisms of action of the BARX1 gene across different tissue developmental processes and disease contexts.
Role of BARX1 in Development and Disease
Homeobox genes encode diverse proteins, including proteins with highly conserved DNA‐binding domains, and are essential for organismal growth, cell differentiation, organ development, and diverse physiological processes associated with diseases. BARX1 encodes a transcription factor containing the BarH1‐like homeodomain. This gene plays a significant role in the development of various tissues and is closely associated with the pathogenesis and progression of numerous diseases. In this review, we provide a comprehensive overview of the functional networks and mechanisms of action of the BARX1 gene across different tissue developmental processes and disease contexts.